InSite Vision, Inc.
| OTC Markets: INSV
InSite Vision, Inc. develops and markets ophthalmic pharmaceutical products. It is an ophthalmic product development company advancing ophthalmic pharmaceutical products for unmet eye care needs based on its DuraSite platform technologies. The DuraSite and DuraSite 2 drug delivery systems extend the duration of drug retention on the surface of the eye, thereby reducing the frequency of treatment and improving the efficacy of topical drugs. The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite and Besivance. The company products include AzaSite, Besivance, AzaSite Plus (ISV-502), DexaSite (ISV-305), BromSite (ISV-303), ISV-101, AzaSite Xtra (ISV-405), ISV-102, ISV-620 and ISV-215. InSite Vision was founded by Merwin Jerry Hansen in 1986 and is headquartered in Alameda, CA.